We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-4.05%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$91.4M
AUM Growth
+$35.6M
(+64%)
Cap. Flow
+$43.1M
Cap. Flow
% of AUM
47.16%
Top 10 Holdings %
Top 10 Hldgs %
62.05%
Holding
42
New
9
Increased
17
Reduced
3
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$9.5M |
| 2 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$6.48M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$5.8M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$3.18M |
| 5 |
Guardant Health
GH
|
+$3.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$2.72M |
| 2 |
Viatris
VTRS
|
+$2.67M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$1.72M |
| 4 |
Centene
CNC
|
+$1.71M |
| 5 |
AbbVie
ABBV
|
+$1.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.87% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $10.5M | 11.48% |
249,866
+207,178
| +485% | +$9.5M |
|
|
BMY.RT
2
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $9.06M | 9.91% |
2,384,487
+1,968,556
| +473% | +$6.48M |
|
3
Baxter International
BAX
$13.5B
| $6.15M | 6.72% |
75,737
+23,545
| +45% | +$2.03M |
|
|
4
Guardant Health
GH
$21.7B
| $5.32M | 5.82% |
76,438
+41,202
| +117% | +$3.16M |
|
5
BioMarin Pharmaceuticals
BMRN
$11.6B
| $4.62M | 5.05% |
54,676
+20,895
| +62% | +$1.8M |
|
6
PTC Therapeutics
PTCT
$5.68B
| $4.48M | 4.9% |
100,470
+45,062
| +81% | +$2.27M |
|
7
Bio-Rad Laboratories Class A
BIO
$8.71B
| $4.44M | 4.86% |
12,676
+6,325
| +100% | +$2.33M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.42M | 4.84% |
+86,577
| New | +$5.8M |
|
9
UnitedHealth
UNH
$376B
| $3.94M | 4.31% |
15,811
+9,397
| +147% | +$2.59M |
|
10
Twist Bioscience
TWST
$5.7B
| $3.8M | 4.15% |
124,120
+69,786
| +128% | +$1.88M |
|
|
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $3.41M | 3.73% |
72,712
+49,689
| +216% | +$3.18M |
|
12
Ascendis Pharma A/S
ASND
$16B
| $3.17M | 3.47% |
28,157
+21,610
| +330% | +$2.81M |
|
|
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
| $2.94M | 3.22% |
318,152
+219,434
| +222% | +$2.09M |
|
14
Fate Therapeutics
FATE
$286M
| $2.67M | 2.92% |
+120,103
| New | +$3.04M |
|
15
Cytokinetics
CYTK
$10.5B
| $2.41M | 2.63% |
204,251
+119,079
| +140% | +$1.52M |
|
|
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2.26M | 2.47% |
83,087
+20,502
| +33% | +$571K |
|
17
Tandem Diabetes Care
TNDM
$1.34B
| $2.08M | 2.27% |
32,292
-11,267
| -26% | -$789K |
|
|
VAR
18
DELISTED
Varian Medical Systems, Inc.
VAR
| $1.79M | 1.96% |
17,484
+11,550
| +195% | +$1.53M |
|
|
NSTG
19
DELISTED
NanoString Technologies, Inc.
NSTG
| $1.79M | 1.96% |
+74,501
| New | +$2.16M |
|
|
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.74M | 1.9% |
213,830
+125,117
| +141% | +$1.08M |
|
21
uniQure
QURE
$3.03B
| $1.53M | 1.68% |
+32,331
| New | +$1.86M |
|
22
10x Genomics
TXG
$6B
| $1.53M | 1.68% |
+24,603
| New | +$1.92M |
|
23
Sarepta Therapeutics
SRPT
$1.57B
| $1.47M | 1.61% |
+15,016
| New | +$1.72M |
|
|
TECX
24
Tectonic Therapeutic
TECX
$529M
| $1.33M | 1.46% |
+7,130
| New | +$1.68M |
|
|
IMMU
25
DELISTED
Immunomedics Inc
IMMU
| $1.24M | 1.36% |
+92,147
| New | +$1.55M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Asymmetry Capital Management held 42 positions worth $91.4M, up 64% from $55.8M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Asymmetry Capital Management deployed $43.1M of net new capital in Q1 2020, opening 9 new positions and adding to 17 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 86,577 shares worth $4.42M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Centene, an estimated $1.71M trimmed.
- Asymmetry Capital Management's largest Q1 2020 buy was Global Blood Therapeutics, Inc.: 86,577 shares worth $4.42M.
- Asymmetry Capital Management added most to Arena Pharmaceuticals Inc in Q1 2020, an estimated $9.5M increase.
- Asymmetry Capital Management's biggest Q1 2020 reduction was Centene, cutting an estimated $1.71M.
- Asymmetry Capital Management fully exited Insmed in Q1 2020, selling an estimated $2.72M.
- Asymmetry Capital Management's ten largest holdings make up 62% of its $91.4M portfolio in Q1 2020.
- Asymmetry Capital Management opened 9 new positions and closed 13 in Q1 2020.
- Asymmetry Capital Management's portfolio value rose 64% quarter-over-quarter to $91.4M.
Based on Asymmetry Capital Management's 13F filing for Q1 2020, filed 13 May 2020.